Fresh analysis indicates that patients who stop using popular slimming jabs like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who stop conventional diet and exercise plans.
Findings released in a leading medical journal demonstrates that while obese individuals often shed substantial amounts of their body weight while using the jabs, the mass comes back at an average rate of nearly a kilo each month after stopping.
"People using such treatments must be aware of the potential of quick weight regain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to pre-treatment mass in about a year and a half.
Analyzing Therapies
The study, which examined dozens of trials involving thousands of participants, contrasted the effects of GLP-1 agonists with older methods.
The team note that individuals who shed pounds through lifestyle changes alone generally see a more gradual weight regain—approximately 100 grams monthly—once they finish.
The Reason for the Quick Rebound
Doctors propose the mechanism of the drugs is key to understanding the accelerated weight return.
These medications imitate a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Artificially providing the hormone concentrations far above than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this medication means hunger is no longer kept in check, making excessive eating much more probable."
A Chronic Condition?
Medical guidelines suggest the injections for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, due to the likelihood of weight regain, the therapy should be considered life-long.
This perspective is reinforced by pharmaceutical companies, who state that the findings "underscore the long-term nature of excess weight," comparing it to managing diseases like hypertension.
Patient Testimonies
Users who have come off the jabs explain a sudden return of hunger.
"I experienced a switch that goes on and you become extremely hungry," said a patient.
This challenge is exacerbated if users have not established sustainable lifestyle or habit modifications during therapy.
Widespread Use
Figures suggest that millions of people in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.
- Adoption is higher among females compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a permanent cure and maintained weight loss hinges on combined behavioural support.
